Finance

Beta
Lists
BIOFILCHEM:NSE
Biofil Chemicals and Pharmaceuticals Ltd
β‚Ή36.39
+2.80%
(+0.99) 1D
Jun 19, 3:30:00β€―PM GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOFILCHEM...
Open
β‚Ή35.40
High
β‚Ή36.40
Low
β‚Ή34.55
Mkt. cap
586.67M
Avg. vol.
104.66K
Volume
35.30K
P/E ratio
21.28
52-wk high
β‚Ή49.00
52-wk low
β‚Ή25.60
EPS
β‚Ή1.71
No. of employees
26
Open
β‚Ή35.40
High
β‚Ή36.40
Low
β‚Ή34.55
Mkt. cap
586.67M
Avg. vol.
104.66K
Volume
35.30K
P/E ratio
21.28
52-wk high
β‚Ή49.00
52-wk low
β‚Ή25.60
EPS
β‚Ή1.71
No. of employees
26
News stories
From sources across the web
About Biofil Chemicals and Pharmaceuticals Ltd
CEO-
Employees26
Founded1985
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in INR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in INR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
92.65M
136.04M
9.35M
76.74M
Cost of goods sold
59.90M
131.71M
4.25M
66.38M
Cost of revenue
59.90M
131.71M
4.25M
66.38M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.69M
2.55M
3.36M
4.93M
Operating expense
3.35M
3.21M
4.02M
5.67M
Total operating expenses
63.24M
134.92M
8.27M
72.05M
Operating income
29.40M
1.12M
1.07M
4.69M
Other non operating income
-1.68M
-
-
-
EBT including unusual items
27.62M
1.12M
1.07M
4.69M
EBT excluding unusual items
27.62M
1.12M
1.07M
4.69M
Income tax expense
3.52M
281.00K
275.00K
2.57M
Effective tax rate
12.72%
25.16%
25.77%
54.74%
Other operating expenses
-
-
-
-
Net income
24.11M
836.00K
792.00K
2.12M
Net profit margin
26.02%
0.61%
8.47%
2.77%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-93.00K
-1.00K
-5.00K
-2.00K
Net interest expenses
-93.00K
-1.00K
-5.00K
-2.00K
Depreciation and amortization charges
660.00K
660.00K
660.00K
741.00K
EBITDA
30.35M
1.78M
2.02M
5.37M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more